Syed Shafi Asghar, Ph.D.

Division of Biochemistry and Immunology, Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Amsterdam, The Netherlands

Received 12/08/95; Accepted 26/01/96; On-line 03/01/96

Key words: Complement; Pharmacological manipulation; Complement inhibitors; Complement regulatory molecules; Intravenous immunoglobulin; Autoimmune diseases; Inflammation; Xenotransplantation.

TABLE OF CONTENTS

1. Introduction

2. The complement system

3. Regulators of complement activation

4. Therapeutic uses of high molecular weight inhibitors of complement

4.1. C1-inhibitor

4.1.1. Treatment of HANE

4.1.2. Control of toxicity caused by IL-2 immunotherapy

4.1.3. Treatment of sepsis

4.2. Intravenous immunoglobulin

4.2.1. Autoimmune thrombocytopenic purpura

4.2.2. Kawasaki disease

4.2.3. Myasthenia gravis

4.2.4. Chronic inflammatory demyelinating polyneuropathy

4.2.5. Other diseases

4.3. Factor I, factor H and C4-binding protein (C4BP)

4.3.1. Factor I deficiency

4.4. Decay accelerating factor (DAF), membrane cofactor protein (MCP) and complement receptor 1(CR1)

4.4.1. DAF

4.4.1.1. Immune complex-induced inflammation

4.4.1.2. Xenotransplantation

4.4.2. CR1

4.4.2.1. Reperfusion injury

4.4.2.2. Thermal trauma

4.4.2.3. Hyperacute rejection

4.4.2.4. Immune complex-mediated inflammation

4.4.2.5. Other experimental models

4.4.3. CD59

4.4.3.1. Xenotransplantation

5. Concluding remarks

6. References

7. Entire manuscript

Search OMIM (Online Mendelian Inheritance in Man) to find related articles
This form requires a WWW Client such as Netscape, XMosaic, Lynx that supports fill-in forms.